Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
FSHD Header Logo
mobile-logo

  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Journey To A Cure
          • 2022 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • Patient Involvement
          • True Cost of FSHD Study
          • Clinical Trials
          • Donate tissue
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • FSHD Connect Conference
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Clinical Trials
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • Global Collaboration
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Project Mercury
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • JOIN US
  • Donate
  • JOIN US
  • Donate

aTyr Pharma to advance Resolaris™ clinical programs

Home / FSHD Research / aTyr Pharma to advance Resolaris™ clinical programs

Posted on: Apr 20, 2016

aTyrLogoThe San Diego-based biotech company, aTyr Pharma, Inc., released findings on March 30, 2016, from a Phase 1b/2 clinical trial of its experimental therapy Resolaris in adult facioscapulohumeral muscular dystrophy (FSHD) patients. While the number of patients in the study is small, the company stated that the favorable safety, tolerability, immunogenicity and activity profile of Resolaris as demonstrated in this study warrants advancing its clinical programs in adult FSHD patients and potentially other rare diseases.

The randomized, double-blind, placebo-controlled trial studied Resolaris in three dose escalation cohorts (0.3, 1.0, and 3.0 mg/kg) across four sites and a total of 20 patients. The study was designed to evaluate the safety, tolerability, immunogenicity (immune reaction to Resolaris) and pharmacokinetic (PK) profile of Resolaris in adult FSHD patients. The study also evaluated the usefulness of tools that could potentially measure drug effectiveness, such as magnetic resonance imaging (MRI) and patient reported outcomes.

Patients were treated and followed for 1 month for the first two cohorts and 3 months for the third cohort. The study did not observe any difference in the MRI between controls and patients receiving the drug after three months of treatment, but it found that data from a patient reported outcome measure suggests potential improvement, primarily in the categories of activities, independence and emotions. The findings were felt to be encouraging enough to justify continuing the development of Resolaris in FSHD and other rare myopathies with an immune component and potentially expanding the trial to additional clinical trial sites.

The company is currently recruiting for a 12-week trial for patients between the ages of 16 and 25 who had onset of FSHD symptoms before age 10, and is conducting a 12-week trial for adults with FSHD or limb-girdle muscular dystrophy type 2B (LGMD2B). Trial details and sites are posted here.

Read aTyr’s press release here. 

Update: aTyr Pharma announces second quarter 2016 operating results (PRWeb)

Share

Filed Under: FSHD Research

Comments

  1. Karen Weber says

    April 26, 2016 at 12:56 am

    How can FSHD patients get involved in the clinical trials?

    Reply
    • June Kinoshita says

      April 26, 2016 at 11:34 am

      Visit our Find a Clinical Study page to learn about current opportunities to volunteer for a trial or study:
      https://www.fshdsociety.org/find-a-clinical-trial/

      Reply
  2. Fred Harrington says

    August 10, 2016 at 11:20 am

    Placebo-testing plays such an important role in the study of these drugs. Thanks for the above link for volunteers!

    Reply
  3. Ruby says

    June 20, 2018 at 8:19 am

    How can you get Resolaris if you live in Canada?

    Reply
    • June Kinoshita says

      July 23, 2018 at 11:21 am

      Hi Ruby, The Resolaris trial has ended and the company does not have plans at present to start a new trial. There are Canadian sites for Acceleron’s ACE-083 trial.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
    • Journey to a Cure
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

Mail Donations to:

Department 960
PO Box 4106
Woburn, MA 01888-4106

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by